Sartorius AG

Common Name
Sartorius
Country
Germany
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
13,685
Ticker
SRT
Exchange
XETRA
Description
Sartorius AG is a prominent global provider in the field of laboratory and pharmaceutical equipment. Recognized especially for its expertise in providing cutting-edge solutions for the biopharmaceutic...

Sartorius's Financial Statements Preview

Below are the financial statements of Sartorius, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in billions of EUR
2024
2023
Sales revenue
3.38a
3.4a
Cost of sales
-1.86a
-1.83a
Gross profit on sales
1.52a
1.57a
Selling and distribution expenses
-0.67a
-0.63a
Research and development expenses
-0.2a
-0.17a
General administrative expenses
-0.21a
-0.21a
Other operating income
0.05a
0.07a
Other operating expenses
-0.1a
-0.12a
Earnings before interest and taxes (EBIT)
0.39a
0.5a
Financial income
0.06a
0.1a
Financial expenses
-0.27a
-0.22a
Financial result
-0.21a
-0.12a
Profit before tax
0.19a
0.39a
Income taxes
-0.05a
-0.1a
Net profit for the period
0.14a
0.29a
Attributable to
Equity holders of Sartorius AG
0.08a
0.21a
Non-controlling interest
0.05a
0.09a
Download Data

Verified Sources Behind Sartorius’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sartorius’s data sources below and access millions more through our Disclosure Search.

a. Sartorius's Annual Report 2024
a. Sartorius's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?